In the News: Vivasc Therapeutics Receives Its Second NIH Phase I STTR Grant
Our Aim
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner.
We are actively seeking partners to use CTP as a platform vector to deliver therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytes.